Guangdong Hengrui Pharmaceutical Co., Ltd
Clinical trials sponsored by Guangdong Hengrui Pharmaceutical Co., Ltd, explained in plain language.
A subsidiary of Jiangsu Hengrui Pharmaceuticals, involved in the development and manufacturing of pharmaceutical products.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- New shot for eczema shows promise in early trial Results expected Sep 2026 (estimated)
- New inhaled powder for COPD heads into first human tests Results expected Sep 2026 (estimated)
- New inhaler hope for COPD patients in early trial Results expected Oct 2026 (estimated)
- New injection could tame seasonal allergy symptoms for those failed by standard treatments Results expected Dec 2026 (estimated)
- Can an experimental injection clear stubborn psoriasis? a new trial aims to find out. Results expected Dec 2026 (estimated)
-
New injection for obesity tested for safety in first human trial
Disease control Not yet recruitingResearchers are testing an experimental injectable drug called SHR-1179 in obese adults. The trial aims to see how safe and tolerable a single dose is, and how the body processes the drug. About 50 participants with a body mass index between 28 and 35 will receive either SHR-1179…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Sep 19, 2026 00:00 UTC
-
Can a new injection clear psoriasis when other biologics fail?
Disease control Not yet recruitingThis phase II trial is testing an investigational drug called SHR-1139 in adults with plaque psoriasis who have not responded well to at least one biologic treatment. Participants will receive either SHR-1139 or a placebo via subcutaneous injection over a 52-week treatment period…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
Could a new injection tame ulcerative colitis?
Disease control Not yet recruitingThis early-stage trial is testing an experimental drug called SHR-7590 to see if it is safe and tolerable when given by injection under the skin or into a vein. It involves healthy volunteers and people with moderate-to-severe ulcerative colitis, a condition that causes inflammat…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Aug 13, 2026 00:00 UTC
-
New hope for myasthenia gravis patients: experimental drug enters phase 2 trial
Disease control Not yet recruitingThis study tests whether SHR-2173, added to usual care, improves symptoms of generalized myasthenia gravis (gMG) better than a placebo. About 60 adults with confirmed gMG will receive the drug or placebo for 24 weeks. The main goal is to see if daily muscle weakness and fatigue s…
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 13:00 UTC
-
New hope for painful skin ulcers: experimental drug enters human trials
Disease control Not yet recruitingThis phase 2 study tests an injection called SHR-1139 in 20 adults with pyoderma gangrenosum, a rare condition causing painful skin ulcers. The goal is to see if the drug can completely close the ulcers and how safe it is. Researchers will also measure how the body processes the …
Phase 2 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 09:09 UTC
-
Easier injections for asthma? study tests two delivery methods
Knowledge-focused Not yet recruitingThis study tests whether a prefilled autoinjector delivers the drug SHR-1703 as effectively as a standard prefilled syringe in healthy adults. The goal is to see if the autoinjector provides a similar level of drug in the blood, which could make future injections easier for peopl…
Phase 1 • Sponsor: Guangdong Hengrui Pharmaceutical Co., Ltd • Aim: Knowledge-focused
Last updated Jul 16, 2026 00:00 UTC